KoreaMed Synapse
About Synapse
Overview
Help
Disclaimer
 
          
         Journal List > Korean J Ophthalmol > v.26(1); Feb 2012
  | Full Text   | Links   |
Korean J Ophthalmol. 2012 Feb;26(1):21-25.
Published online 2012 Jan 14.  http://dx.doi.org/10.3341/kjo.2012.26.1.21
© 2012 The Korean Ophthalmological Society
Clinical Outcomes of Cyclosporine Treatment for Noninfectious Uveitis
Sun Ho Lee,1 Hum Chung,2 and Hyeong Gon Yu2,3
1Department of Ophthalmology, Jeju National University Hospital, Jeju, Korea.
2Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.
3Research Institute for Sensory Organs, Medical Research Center, Seoul National University, Seoul, Korea.

Corresponding Author: Hyeong Gon Yu, MD, PhD. Department of Ophthalmology, Seoul National University Hospital, #28 Yeongeon-dong, Jongno-gu, Seoul 110-744, Korea. Tel: 82-2-2072-3083, Fax: 82-2-741-3187, Email: hgonyu@snu.ac.kr
Received October 16, 2010; Accepted February 21, 2011.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract

Purpose

To assess the clinical outcomes of cyclosporine treatment for noninfectious uveitis.

Methods

A retrospective review of medical records was completed for 182 noninfectious uveitis patients who were treated with cyclosporine between January 2001 and August 2010. Data was obtained relevant to demographic characteristics, anatomic classification, and laterality of uveitis, associated systemic disorder, dosage of cyclosporine and prednisolone, usage of other immunosuppressive drugs, visual acuity (VA), control of uveitic activity, and adverse effects during the cyclosporine use.

Results

Uveitic activity was controlled to a level of minimal inflammation in 89.0% and completely in 78.6% of patients by the median duration of 49 and 98 days, respectively. Prednisolone-sparing (dose ≤10 mg) control of inflammation equal to or less than the minimal activity was achieved in 75.3% of patients. VA was aggravated more than 0.2 logarithm of the minimum angle of resolution in 17.3% of eyes in spite of cyclosporine treatment for the mean follow-up of 698.4 days. Dose reduction and cessation of cyclosporine was required only in 3.3% and 9.3%, respectively, due to the intolerable toxicity, although 44.0% of patients experienced mild to moderate adverse effects.

Conclusions

Cyclosporine combined with corticosteroids or other immunosuppressive drugs as needed is an effective treatment for noninfectious uveitis, thus minimizing the adverse effects of corticosteroids and other toxic drugs. However, careful monitoring for the toxicity of cyclosporine is needed, because a small group of patients cannot tolerate its toxicity.

Keywords: Adrenal cortex hormones, Cyclosporine, Immunosuppressive agent, Uveitis.
References
1. Murphy KP, Travers P, Walport M. Manipulation of the immune response. In: Murphy KP, Jameway C, Travers P, Walport MJaneway's immunobiology. 7th ed. New York: Garland Science; 2008. pp. 659-660.
2. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983;96:275–282.
3. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978;2:1323–1327.
4. Nussenblatt RB, Mittal KK, Ryan S, et al. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 1982;94:147–158.
5. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1985;1:369–382.
6. Binder AI, Graham EM, Sanders MD, et al. Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol 1987;26:285–291.
7. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988;20 3 Suppl 4:136–143.
8. Le Hoang P, Girard B, Deray G, et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc 1988;20 3 Suppl 4:128–130.
9. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989;1:1093–1096.
10. De Vries J, Baarsma GS, Zaal MJ, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990;74:344–349.
11. Secchi AG, Tognon MS, Maselli C. Cyclosporine-A in the treatment of serpiginous choroiditis. Int Ophthalmol 1990;14:395–399.
12. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991;112:138–146.
13. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992;76:241–243.
14. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology 1994;101:822–831.
15. Araujo AA, Wells AP, Dick AD, Forrester JV. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol 2000;84:979–982.
16. Michel SS, Ekong A, Baltatzis S, Foster CS. Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology 2002;109:378–383.
17. Ozdal PC, Ortac S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol 2002;105:301–312.
18. Becker MD, Wertheim MS, Smith JR, Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm 2005;13:289–293.
19. Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 2005;112:1066–1071.
20. Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117:576–584.
21. Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol 2010;58:55–58.
22. Kim HB, Kim EK, Park K, Chung H. Results of cyclotporin A therapy in Behcet's disease. J Korean Ophthalmol Soc 1990;31:469–475.
23. Lee ET, Kim MH, Chung SM. The effect of cyclosporin therapy on endogenous uveitis. J Korean Ophthalmol Soc 1997;38:601–607.
24. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492–513.
25. Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509–516.
26. Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond) 2009;23:1192–1198.
27. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 2002;13:2962–2968.